INTRODUCTION
============

Ovarian cancer is the leading cause of death from gynecologic malignancy \[[@B1]\]. In Korea, ovarian cancer incidence and mortality rates have recently increased \[[@B2][@B3]\]. Primary debulking surgery (PDS) followed by platinum-based chemotherapy is currently the standard treatment for advanced-stage ovarian cancer \[[@B4]\]. Recently, several randomized clinical trials have shown that neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) is not inferior to PDS with respect to survival, postoperative morbidity, and mortality in women with stage III or IV ovarian cancer \[[@B5][@B6][@B7][@B8]\]. Therefore, NAC followed by IDS is considered a feasible alternative approach in advanced-stage ovarian cancer \[[@B9]\].

To date, few studies have examined the impact of the increased adoption of NAC as a primary treatment for advanced-stage ovarian cancer in clinical practice, where the choice between PDS and NAC remains controversial. Two meta-analyses investigated the outcomes of NAC but reported contradictory findings \[[@B10][@B11]\]. In our institution, PDS has been the standard treatment strategy for patients with advanced-stage ovarian cancer. In addition, NAC has been used for patients who were considered unsuitable for optimal PDS or who had significant medical comorbidities.

The European Organization for Research and Treatment of Cancer (EORTC) trial \[[@B6]\] demonstrated that survival outcomes after NAC were comparable to those of PDS. The median progression-free survival (PFS) was 12 months for both the PDS and NAC groups, whereas median overall survival (OS) was 29 and 30 months for the PDS and NAC groups, respectively. Importantly, the NAC group had higher rates of complete gross resection and lower rates of major postoperative complications. Since the publication of the EORTC 55971 trial outcomes, our institution increased the utilization of NAC in patients with advanced-stage ovarian cancer, fallopian tube cancers, or primary peritoneal carcinomas.

The purpose of the present study was to compare the survival outcomes before and after the increased adoption of NAC in our center\'s practice of treating advanced-stage ovarian cancer. We hypothesized that this paradigm shift would lead to an increased rate of no gross residual disease without increasing the rates of major perioperative complications.

MATERIALS AND METHODS
=====================

1. Study population {#sec1}
-------------------

We performed a retrospective review of the medical records of patients with pathology-confirmed International Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian cancer treated at Yonsei Cancer Hospital, who received PDS or NAC between 2006 and 2014. The following patients were excluded: patients who did not undergo PDS or IDS after NAC (n=9); patients lost to follow-up (n=21); patients whose medical records were not available (n=12). The final study population comprised 435 patients.

NAC has been used in our institution since late 2010. Therefore, we stratified the patients into 2 groups according to the period in which they were treated. Group 1 (control group) consisted of 216 patients who had been diagnosed between January 1, 2006 and December 31, 2010; most patients in this group underwent PDS. Group 2 (study group) consisted of 219 patients who were diagnosed between January 1, 2011 and December 31, 2014, during which time our center had adopted increased utilization of NAC for advanced-stage ovarian cancer, fallopian tube cancer, and primary peritoneal carcinomas.

The diagnosis was established based on open surgery, laparoscopic, or imaging-biopsy samples or based on fine-needle aspiration samples obtained from the tumor site or ascites/effusion. All surgical procedures were performed by one of the 5 gynecologic oncology surgeons at our institute. The histological diagnoses were based on World Health Organization criteria, and all microscope slides were reviewed by [@B2] experienced gynecologic pathologists. NAC was performed if at least one of the following 3 criteria was met: 1) presence of pulmonary and/or hepatic parenchymal metastases on imaging studies before surgery; 2) medically inoperable cancer; and/or 3) optimal cytoreduction infeasible because of high tumor burden (Fagotti score ≥8) as observed on diagnostic laparoscopy \[[@B12][@B13]\]. Standard surgical procedures included the following: sampling of free fluid or peritoneal washings for cytology; thorough inspection of the abdomen and pelvis, including the upper abdominal viscera, diaphragm, and retroperitoneal spaces; and hysterectomy, bilateral oophorectomy and omentectomy, pelvic/para-aortic lymph node dissection, and appendectomy. Radical surgery included bowel resection, diaphragm or other peritoneal surface stripping, splenectomy, partial hepatectomy, partial gastrectomy, or partial cystectomy with or without ureteroneocystostomy, cholecystectomy, and/or distal pancreatectomy \[[@B14][@B15][@B16]\]. Surgical complexity was classified, per previously published protocols, as low, intermediate, or high \[[@B17]\]. A different score was assigned to each surgical procedure ranging from 1 to 3 according to the complexity of the procedure. The surgical procedure assigned to 1 are hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic lymphadenectomy, para-aortic lymphadenectomy, abdominal peritoneum stripping, small bowel resection, small bowel resection, 2 are large bowel resection, diaphragm stripping/resection, splenectomy, liver resection, and 3 is recto-sigmoidectomy with anastomosis. Perioperative complications were graded using the Memorial Sloan-Kettering Cancer Center\'s (MSKCC) surgical secondary events grading system \[[@B18]\]. Major complications were defined as events with MSKCC grade ≥3. Perioperative morbidity was defined as any adverse events (AEs) related to treatment occurring within 30 days of surgery. Operative mortality was defined as death occurring within 30 days after surgery (MSKCC grade 5). The present study was reviewed and approved by the Institutional Review Board of Yonsei Cancer Hospital (registration number: 4-2017-0998).

2. Statistical analysis {#sec2}
-----------------------

SPSS statistical software (version 21.0; IBM Corp., Armonk, NY, USA) was used for the statistical analyses. Descriptive statistics were used for demographic data and are summarized as the median (range) or frequency (percentage). Differences in the patient characteristics associated with the 2-time intervals were assessed using the χ^2^ or Mann-Whitney U test. The study endpoints included PFS and OS. PFS was defined as the interval between the date of diagnosis and the date of the first recurrence. OS was defined as the interval between the date of diagnosis and the date of death. The date of recurrence was defined as the date of disease detection via radiology during follow-up. An increase in cancer antigen 125 (CA-125) levels without clinical signs of relapse was not regarded as progression but commonly necessitated radiological examinations. PFS and OS were analyzed using the Kaplan-Meier method and log-rank test. Factors identified as significant in the univariate analyses were entered into multivariate analysis. Cox regression analysis was used to evaluate the effects of the prognostic factors, expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). For all analyses, p\<0.05 was considered to indicate statistical significance.

RESULTS
=======

A total of 435 consecutive patients undergoing PDS or NAC at our institution were evaluated over the study period. A comparison of patient and clinical characteristics between group 1 and group 2 is shown in [Table 1](#T1){ref-type="table"}. There were no significant between-group differences in patient characteristics such as age, body mass index, tumor grade, or histologic type. The distribution of FIGO stages was significantly different between the 2 groups: group 1, 64 (29.6%) stage IV patients; group 2, 126 (57.5%) stage IV patients (p\<0.001). Performance status was also different between the 2 groups, with 2.3% and 19.7% of patients having American Society of Anesthesiologists (ASA) score ≥3 in groups 1 and 2, respectively (p\<0.001). The median CA-125 level was significantly different between the 2 groups: group 1, 897.1 U/mL (range, 8.7--30,008.8); group 2, 1,474.1 U/mL (range, 12.9--30,000.0; p=0.003).

###### Patient and clinical characteristics

![](jgo-29-e63-i001)

  Characteristics                Group 1 (n=216)                      Group 2 (n=219)            p
  ------------------------------ ------------------------------------ -------------------------- ------------
  Age (yr)                       56 (22--83)                          55 (26--79)                0.779
  BMI (kg/m^2^)                  22.9 (16.0--40.3)                    22.5 (16.4--34.4)          0.530
  FIGO stage                                                                                     \<0.001
                                 III                                  152 (70.4)                 93 (42.5)
                                 IV                                   64 (29.6)                  126 (57.5)
  Tumor grade                                                                                    0.214
                                 1                                    16 (7.4)                   11 (5.0)
                                 2                                    72 (33.4)                  62 (28.3)
                                 3                                    107 (49.5)                 113 (51.6)
                                 Not available                        21 (9.7)                   33 (15.1)
  Histologic type                                                                                0.696
                                 Serous                               174 (80.6)                 179 (82.1)
                                 Endometrioid                         10 (4.6)                   5 (2.3)
                                 Mucinous                             14 (6.5)                   14 (6.4)
                                 Clear cell                           9 (4.2)                    12 (5.5)
                                 Other                                9 (4.2)                    9 (3.7)
  ASA score                                                                                      \<0.001
                                 1                                    128 (59.3)                 60 (27.4)
                                 2                                    77 (35.6)                  110 (50.2)
                                 3                                    5 (2.3)                    42 (19.2)
                                 4                                    0 (0)                      1 (0.5)
                                 Not available                        6 (2.8)                    6 (2.7)
  Median CA-125 level (U/mL)     897.1 (8.7--30,008.8)                1,474.1 (12.9--30,000.0)   0.003
  NAC                                                                                            \<0.001
                                 Yes                                  35 (16.2)                  107 (48.9)
                                 No                                   181 (83.8)                 112 (51.1)
  Chemotherapy regimen                                                                           0.006
                                 Paclitaxel+carboplatin               156 (72.2)                 171 (78.1)
                                 Docetaxel+carboplatin                25 (11.6)                  36 (16.4)
                                 Paclitaxel+carboplatin+bevacizumab   1 (0.5)                    3 (1.4)
                                 Paclitaxel+cisplatin                 2 (0.9)                    3 (1.4)
                                 IP chemotherapy                      28 (13.0)                  0 (0)
                                 Others                               2 (0.9)                    2 (0.9)
                                 Not available                        2 (0.9)                    4 (1.8)
  Cycles of total chemotherapy                                                                   0.005
                                 ≤6                                   158 (73.1)                 132 (60.3)
                                 \>6                                  58 (26.9)                  87 (39.7)

Values are presented as median (range) or number (%).

ASA, American Society of Anesthesiologists; BMI, body mass index; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; IP, intraperitoneal; NAC, neoadjuvant chemotherapy.

Among the entire cohort, 142 of 435 patients (32.6%) received NAC and 293 of 435 patients (67.4%) underwent PDS. In groups 1 and 2, 16.2% and 48.9% of patients, respectively, underwent NAC (p\<0.001). The change in NAC use between 2006 and 2014 is shown in [Fig. 1](#F1){ref-type="fig"}. Regarding the chemotherapy regimen, the use of intraperitoneal (IP) chemotherapy was different between the 2 groups (13.0% vs. 0%, p=0.006). The median number of chemotherapy cycles was 6 (range, 1--12 cycles) in both groups. In groups 1 and 2, 58 (26.9%) and 87 (39.7%) patients, respectively, received more than 6 cycles of chemotherapy, with a significant difference between the 2 groups (p=0.005). Across the study period, the rate of no-gross residual disease increased from 10.2% to 21.5% (p\<0.001). This was followed by an increase in the rate of radical surgery from 35.6% in group 1 to 57.5% in group 2 (p\<0.001). Surgical complexity was also higher in group 2 (high-surgical complexity in 3.7% and 12.8% of patients from groups 1 and 2, respectively; p=0.002). There were 2 (3.7%) and 1 (0.5%) 30-day postoperative deaths (grade 5 events) in groups 1 and 2, respectively. There were 10 (4.7%) and 13 (6.0%) grade 3 or 4 AEs in group 1 and 2, respectively. Major postoperative morbidity (restricted to grade 3--5) was not different between the 2 groups (5.6% vs. 6.4%, p=0.465) despite the increase in surgical complexity ([Table 2](#T2){ref-type="table"}).

![Change in NAC use between 2006 and 2014.\
NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery.](jgo-29-e63-g001){#F1}

###### Classification of postoperative outcomes according to the Memorial Sloan-Kettering Cancer Center\'s surgical secondary events grading system

![](jgo-29-e63-i002)

  Variables                             Group 1 (n=216)       Group 2 (n=219)   p
  ------------------------------------- --------------------- ----------------- ------------
  Complication grade^\*^                                                        0.068
                                        0                     102 (47.2)        130 (59.4)
                                        1                     15 (6.9)          9 (4.1)
                                        2                     79 (36.6)         62 (28.4)
                                        3                     10 (4.7)          10 (4.6)
                                        4                     0 (0)             3 (1.4)
                                        5                     2 (3.7)           1 (0.5)
                                        Not available         8 (3.7)           4 (1.8)
  Major complications                                                           0.465
                                        0--2                  196 (90.7)        201 (91.8)
                                        3--5                  12 (5.6)          14 (6.4)
                                        Not available         8 (3.7)           4 (1.8)
  Residual disease                                                              \<0.001
                                        No gross              22 (10.2)         47 (21.5)
                                        ≤1.0 cm               94 (43.5)         111 (50.7)
                                        \>1.0 cm              52 (24.1)         13 (5.9)
                                        Not available         48 (22.2)         48 (21.9)
  PDS                                                                           \<0.001
                                        No gross              16 (8.8)          17 (15.2)
                                        ≤1.0 cm               77 (42.5)         60 (53.6)
                                        \>1.0 cm              49 (27.1)         8 (7.1)
                                        Not available         39 (21.5)         27 (24.1)
  NAC                                                                           0.466
                                        No gross              6 (17.1)          30 (28.0)
                                        ≤1.0 cm               17 (48.6)         51 (47.7)
                                        \>1.0 cm              3 (8.6)           5 (4.7)
                                        Not available         9 (25.7)          21 (19.6)
  Radical surgery^†^                                                            \<0.001
                                        None                  139 (64.4)        93 (42.5)
                                        Any radical surgery   77 (35.6)         126 (57.5)
  Surgical complexity score groups^‡^                                           0.002
                                        1                     1 (0.5)           0 (0)
                                        2                     207 (95.8)        191 (87.2)
                                        3                     8 (3.7)           28 (12.8)

Values are presented as number (%).

NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery.

^\*^According to the Memorial Sloan-Kettering Cancer Center\'s surgical secondary events grading system \[[@B16]\]; ^†^Radical surgery included any of following: bowel surgery, cholecystectomy, diaphragm peritonectomy/resection, distal pancreatectomy video-assisted thoracoscopic surgery, splenectomy, liver resection, supraclavicular fossa resection, ureter resection, and others; ^‡^According to Aletti et al \[[@B17]\].

The Kaplan-Meier curves for OS and PFS are shown in [Fig. 2](#F2){ref-type="fig"}. The median follow-up period was 44.7 months in all patients. The median PFS was 17.6 and 17.0 months for groups 1 and 2, respectively. The median OS for group 1 was 63.3 months, while the median OS in group 2 was not reached. There were no differences in PFS or OS between the groups (p=0.449 and 0.952, respectively). We performed a subgroup analysis of patients who underwent PDS and NAC according to time period ([Supplementary Figs. 1](#S3){ref-type="supplementary-material"} and [2](#S4){ref-type="supplementary-material"}). There were no differences in PFS or OS between the 2 subgroups of patients who underwent PDS (p=0.873 and 0.624, respectively). Similarly, there were no differences in PFS or OS between the 2 subgroups of patients who underwent NAC during the study period (p=0.206 and 0.122, respectively). In addition, we performed subgroup analysis of residual disease (R0, R≤1.0 cm, R\>1.0 cm). Median PFS and OS stratified by residual disease according to year are summarized in [Supplementary Table 1](#S1){ref-type="supplementary-material"} and Kaplan-Meier curves in [Supplementary Figs. 3](#S5){ref-type="supplementary-material"} and [4](#S6){ref-type="supplementary-material"}.

![Kaplan-Meier curves of PFS (A) and OS (B) according to time period (2006--2010 vs. 2011--2014).\
OS, overall survival; PFS, progression-free survival.](jgo-29-e63-g002){#F2}

The results of the multivariate Cox regression analyses of PFS and OS in all patients are shown in [Supplementary Table 2](#S2){ref-type="supplementary-material"}. Residual disease (HR=1.59; 95% CI=1.11--2.27) and high ASA score (HR=1.75; 95% CI=1.12--2.74) were independent prognostic factors associated with a higher risk of progression. In terms of survival, residual disease (HR=2.08; 95% CI=1.24--3.49) and high ASA score (HR=2.02; 95% CI=1.17--3.49) were independent prognostic factors in all patients.

DISCUSSION
==========

In this study, we investigated the impact of the adoption of NAC in our institution\'s clinical practice on survival outcomes of advanced-stage ovarian cancer over the period 9 years. Our analysis demonstrates that the overall NAC use increased from 16.2% to 48.9% between 2006 and 2014 and that the incorporation of NAC increased the rate of complete gross resection in IDS without significantly increasing perioperative morbidity and mortality. There was no improvement in the survival rates during this 9-year period, and the results of multivariate analysis support our findings.

The EORTC 55971 and Chemotherapy OR Upfront Surgery (CHORUS) randomized controlled trials each showed similar survival rates between PDS and NAC groups but with improved optimal resection rates and less perioperative complications in the NAC groups, leading the authors to conclude that NAC is a reasonable treatment option for advanced-stage ovarian cancer \[[@B6][@B7]\]. However, these trials have been criticized because a high number of patients who received PDS had \>1 cm of residual disease after surgery.

At our institution, the incorporation of NAC resulted in increased optimal cytoreduction rates and a similar rate of AEs despite more radical surgery. There was no significant difference in survival outcomes between the 2 groups, although the rate of radical surgery was typically higher in our institution. Various factors potentially associated with increased extent of debulking surgery should be considered, including NAC and extended surgery for advanced-stage ovarian cancer. Primarily, the use of NAC has improved the cytoreduction rates achievable with IDS by reducing the disease burden \[[@B6][@B7]\]. Another important factor was the improvement of surgical skills in our institution during the study period. Specifically, we incorporated radical surgeries in an attempt to decrease residual disease at the time of PDS or IDS. Previous studies reported that radical surgery resulted in higher rates of complete gross resection and optimal resection (residual disease ≤1 cm) in advanced ovarian cancer \[[@B15][@B19][@B20]\]. At our institution, the rate of radical surgery increased from 35.6% in group 1 patients to 57.5% in group 2 patients. MSKCC reported a rate of 38% for extensive upper abdominal procedures in PDS, which is not superior to the rate of radical surgery at our institution. It is noteworthy that the complete resection rates also increased from 10.2% in group 1 to 21.5% in group 2. However, the perioperative complication rate did not differ between the 2 groups even after the incorporation of NAC. These findings are in contrast to the results of previous studies of NAC \[[@B6][@B7][@B8]\]. Fagotti et al. \[[@B8]\] showed that perioperative morbidity rates were more favorable for NAC than for PDS in advanced-stage ovarian cancer patients. Vergote et al. \[[@B6]\] and Kehoe et al. \[[@B7]\] demonstrated less treatment-related perioperative morbidity and mortality in NAC-treated patients than in those who received PDS. However, these studies did not report improvement in surgical methods during the study period. At our institution, the rate of radical surgery increased during the study period, which may have affected the rate and nature of perioperative complications. Radical debulking procedures required for optimal cytoreduction are often associated with significant morbidity and mortality \[[@B15][@B19]\].

The survival outcomes in our study were similar to those reported from the EORTC and CHORUS trials. The median PFS and OS for patients who underwent PDS were 17.7 and 50.5 months, respectively, in our study, compared with 12 and 29 months, respectively, in the EORTC trial and 10.7 and 22.6 months, respectively, in the CHORUS trial. In the subgroup analysis, we found no difference in survival outcomes between groups 1 and 2 for the patients who underwent PDS and NAC following IDS. These findings suggest that the improvement in surgical methods did affect survival outcome in this study, which is in agreement with the findings of the EORTC and CHORUS trials. The 2 groups in the present study received almost the same chemotherapy regimens. Basically, primary combination taxane and platinum-based treatment was administered in both groups and may have contributed to the similar survival outcomes.

One limitation of the present study is the retrospective nature of data collection. Moreover, we included patients who received IP chemotherapy. This is important when considering why survival outcomes did not appear substantially different across the time periods. Several studies showed that IP chemotherapy improved survival outcomes \[[@B21][@B22][@B23]\]. Suidan et al. \[[@B24]\] compared patients receiving primary intravenous (IV)/IP chemotherapy after PDS with those receiving consolidation IV/IP chemotherapy after PDS. Their results revealed improved OS in the primary IV/IP chemotherapy group (78.8 vs. 57.5 months for consolidation chemotherapy). Considering these data, it is possible that IP chemotherapy could have impacted survival outcomes in 13% of patients in group 1.

Our analysis demonstrates that the incorporation of NAC did not affect survival (PFS or OS) or perioperative morbidity and mortality after PDS, but was associated with increased rates of no-gross residual disease. The similar rates of perioperative morbidity and mortality despite more radical surgery and the higher rate of complete resection to no-residual disease suggest that NAC followed by IDS may be important for patients with advanced ovarian cancer. Further studies should evaluate the outcomes of patients treated with NAC in high-volume centers with experience in PDS. Comparative effectiveness research is required to clarify the effects of a paradigm shift toward widespread use of NAC.
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